Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing ...

UnitedHealth Group reported disappointing first-quarter earnings and cut its financial guidance, hit by high costs in its ...